***Welcome to Stillman Translations preliminary onboarding assessment!***

*This assessment has 5 sections. Make sure to follow the instructions and complete all the information needed.*

*The goal of this request is to analyze your performance and your potential.*

*Breathe in and out, and do your best. Hope we can count on you soon!*

**SECTION 1. INSTRUCTIONS**

Below you will find a special instruction for section 3:

\*Please make sure target text mirrors source format.

\*Normalize spaces.

**SECTION 2. GLOSSARY**

*In this section, you are required to complete this task:*

*\*Extract four terms (cells 1 to 4) from the text in Section 3 that you consider are worth being in the glossary.*

|  |  |  |
| --- | --- | --- |
|  | **Source** | **Target** |
| 1 | DB | DB (Denosumab) |
| 2 | D-CARE | D-CARE |
| 3 | Medical care | Atención médica |
| 4 | Markers | Marcadores |

**SECTION 3. TRANSLATION**

Please, add your sample translation below (between 300-500 words). Bear in mind this should be the best sample of your work!

|  |  |
| --- | --- |
| **Source** | **Target** |
| A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of DB as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)  Consent Form Containing Core Component of Study  You are being invited to take part in a research study. Before you decide to participate, it is important for you to understand why the research is being done and what it will involve. Please take as much time as you need to decide whether or not to participate and discuss your participation with family, friends, or your doctor, if you wish. This document, called an informed consent form, provides you with information about the study. You will also be asked if you would like to participate in 2 additional studies, each called a substudy to this study, in 2 separate informed consent forms. Please read this informed consent form carefully and ask any questions you have about the study so you can make an informed decision about your participation. You are under no obligation to take part in this study and, if you decide not to, your future medical care will not be affected in any way. If you have questions at any time while reading this document, please ask your doctor or the study nurse to explain any words or information you do not understand. If after reading this document, you are interested in participating, you will be asked to sign this informed consent form. You will receive a copy of this form to keep.    What is the purpose of this research study?  The purpose of this research study is to evaluate how safe and effective DB is, compared with placebo, in delaying the time it takes for cancer to spread to the bones in subjects with early-stage breast cancer at high risk of recurrence. DB has been approved by some country’s regulatory agencies for certain uses. However, in this current trial DB is considered an investigational product, which means that it has not been approved by an appropriate regulatory agency for the condition being studied. You also will be asked to provide samples of blood and tumor tissue. The samples will be studied to look for special markers that can be used to tailor the use of DB in treating the spread of cancer and/or to study that disease. | Estudio de fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo, del DB como tratamiento adyuvante para mujeres con cáncer de mama en etapa inicial con alto riesgo de recurrencia (D-CARE)  Formulario de consentimiento y componente básico del estudio  Por el presente, se le invita a participar en un estudio de investigación. Antes de decidir participar, es importante que entienda el motivo por el que se realiza la investigación y lo que esto implica. Tómese el tiempo que sea necesario para decidir si desea participar y consulte con su familia, amigos o su médico, sí así lo desea. Este documento, denominado “Formulario de consentimiento informado”, le brinda información sobre el estudio. Además, usted recibirá 2 formularios de consentimiento informado aparte donde se le preguntará si desea participar en 2 estudios adicionales denominados “Subestudios”. Lea cuidadosamente este formulario de consentimiento informado y realice cualquier pregunta que tenga sobre el estudio para poder tomar una decisión informada sobre su participación. Usted no tiene la obligación de participar en este estudio y, si decide no participar, su atención médica no se verá afectada en absoluto en el futuro. Si durante la lectura de este documento tiene alguna duda, consulte a su médico o a la enfermera del estudio para que le explique cualquier término o información que no entienda. Si después de leer este documento decide participar, deberá firmar este formulario de consentimiento informado y recibirá una copia para su registro.    ¿Cuál es el propósito de este estudio de investigación?  El propósito de este estudio de investigación es evaluar cuán seguro y efectivo es el DB (Denosumab), comparado con el placebo, para retrasar el tiempo que demora el cáncer en propagarse a los huesos en mujeres con cáncer de mama en etapa inicial con alto riesgo de recurrencia. El DB fue aprobado por las agencias reguladoras de algunos países para ciertos usos. Sin embargo, en este ensayo actual el DB se considera un producto de investigación, lo que significa que no fue aprobado por una agencia reguladora para la enfermedad que se estudia. Además, usted deberá proporcionar muestras de sangre y tejido tumoral. Estas muestras se analizarán para detectar marcadores especiales que se puedan utilizar para ajustar el uso del DB en el tratamiento de la propagación del cáncer o para estudiar esa enfermedad. |

**SECTION 4. QUESTIONS AND COMMENTS**

We also need to check your capacity to spot potential issues beforehand.

In the table below, please list your questions and comments in relation with this test:

1. Challenging sections from the source text or sections you are unsure of should be copied or inserted into the **Source Text** column.

2. Write your translation in the **Target Text** column.

3. Doubts and comments should be written in English.

|  |  |  |
| --- | --- | --- |
| Source Text | Target Text | Question / Comment  (in English) |
| *A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of DB as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)* | *Estudio de fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo, del DB como tratamiento adyuvante para mujeres con cáncer de mama en etapa inicial con alto riesgo de recurrencia (D-CARE)* | What does D-CARE stand for?  D-CARE stands for Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of DB as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence. D-CARE is the name of the study so it should not be translated. |
| The purpose of this research study is to evaluate how safe and effective DB is, compared with placebo, in delaying the time it takes for cancer to spread to the bones in subjects with early-stage breast cancer at high risk of recurrence. | El propósito de este estudio de investigación es evaluar cuán seguro y efectivo es el DB (Denosumab), comparado con el placebo, para retrasar el tiempo que demora el cáncer en propagarse a los huesos en mujeres con cáncer de mama en etapa inicial con alto riesgo de recurrencia. | What does DB stand for?  It stands for Denosumab. It’s the name of the investigational drug. |
| *The samples will be studied to look for special markers that can be used to tailor the use of DB in treating the spread of cancer and/or to study that disease.* | *Estas muestras se analizarán para detectar marcadores especiales que se puedan utilizar para ajustar el uso del DB en el tratamiento de la propagación del cáncer o para estudiar esa enfermedad.* | What would be the correct translation for “markers” in this context, “indicadores” or “marcadores”?  Both terms are correct. But “marcadores” is the correct medical term used in this context. |
|  |  |  |
|  |  |  |

**SECTION 5. REFERENCES**

In the table below, please list the reference material you have consulted to carry out this test.

1. Please introduce the **Reference source** (including publisher and full title as appropriate) in the first column.
2. Specify if your reference source is general or specific. If specific, clarify which term or section the reference covers.

|  |  |
| --- | --- |
| Reference Source | General / Specific (Term) |
| https://www.researchgate.net/publication/337695838\_Adjuvant\_denosumab\_in\_early\_breast\_cancer\_D-CARE\_an\_international\_multicentre\_randomised\_controlled\_phase\_3\_trial | Specific. To find out the meaning of D-CARE and DB. |
| https://www.cancer.gov/espanol/publicaciones/diccionarios/diccionario-cancer/def/marcador-biologico | Specific. Definition of “markers”. |
|  |  |

Thanks!